Business Context and Reporting Period
Company: ChromaDex Corporation (Note: Input metadata referenced "Niagen Bioscience, Inc.", but the filing text identifies the registrant as ChromaDex Corporation).
Filing Type: Form 8-K (Current Report)
Date of Report: December 13, 2024
Reporting Period: The filing reports a specific corporate governance event effective December 13, 2024, regarding the fiscal year ending December 31, 2024.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a change in accounting firm and does not contain financial statement data.
Material Changes
- Change in Certifying Accountant: The Audit Committee approved the engagement of Crowe LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Effective Date: December 13, 2024.
- Process: The decision followed a competitive request-for-proposal process.
Guidance, Outlook, and Risks
Consultations with New Accountant: The filing states that during the two most recent fiscal years (2022, 2023) and the interim period through December 13, 2024, the Company did not consult Crowe LLP regarding:
- Application of accounting principles to specified transactions.
- Types of audit opinions that might be rendered.
- Any matters constituting a "disagreement" or "reportable event" under Regulation S-K.
Outlook: No specific financial guidance or management commentary on future performance is provided in this filing.
Investor Verification Checklist
- Verify the identity of the registrant (ChromaDex Corporation) versus the metadata label (Niagen Bioscience, Inc.).
- Confirm the transition timeline between the previous auditor and Crowe LLP.
- Review the upcoming 10-K for the fiscal year ending December 31, 2024, to see the first financial statements audited by Crowe LLP.
- Check for any subsequent filings regarding the departure of the previous auditor.